|
|
|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
| Predictive Biomarkers for Upper Tract Urothelial Carcinoma |
| Helen Hougen, MD |
| Sam Chang converses with Helen Hougen about her presentation on predictive biomarkers for upper tract urothelial carcinoma at the SUO, emphasizing their critical role in risk stratification. They delve into the limitations of current diagnostic tools like ureteroscopic biopsies, which often provide imperfect information and pose significant patient burdens. |
|
|
|
|
|
|
|
|
|
|
|
|
Understanding Risk Stratification in Non-Muscle Invasive Bladder Cancer: Applying AUA Guidelines in Clinical Practice
|
|
Neal Shore, MD, FACS
|
| Ashish Kamat is joined by Neal Shore to delve into risk stratification in non-muscle invasive bladder cancer (NMIBC). Dr. Shore highlights the crucial role of the AUA guidelines, developed with significant contributions from Dr. Kamat and others, in differentiating patients into low, intermediate, and high-risk categories.
|
|
|
|
|
|
|
|
|
|
|
|
|
MMAI Model Risk Stratification for NCCN Guidelines for Low, Intermediate, and High-Risk Prostate Cancer
|
|
Daniel Spratt, MD, Alicia Morgans, MD, MPH, and Neal Shore, MD, FACS
|
| Zach Klaassen hosts a multidisciplinary roundtable discussing the NCCN Prostate Cancer Guidelines with a focus on the ArteraAI prostate test. Joined by Dr. Dan Spratt, Dr. Alicia Morgans, and Dr. Neal Shore, they explore the importance of risk stratification in prostate cancer, highlighting the superior predictive and prognostic capabilities of the ArteraAI test compared to traditional methods.
|
|
|
|
|
|
|
|
|
|
|
|
| Head-to-Head Comparison of the American Urological Association and European Association of Urology Risk Stratification Models of Upper Tract Urothelial Carcinoma
|
| Giuseppe Basile, MD
|
| Giuseppe Basile presents a comparison of the American Urological Association (AUA) and European Association of Urology (EAU) risk stratification models for upper tract urothelial carcinoma. The study, based on data from a tertiary care institution, found that while both models effectively stratified patients into low and high-risk groups for disease recurrence and clinical progression after conservative treatment, the EAU model demonstrated superior discriminative ability.
|
|
|
|
|
|
| A Risk Stratification Model for Intermediate-Risk Non-Muscle-Invasive Bladder Cancer
|
| Bishoy M. Faltas, MD
|
| NMIBC represent a heterogeneous group of tumors with variable clinical outcomes. Multiple risk features are incorporated in predicting the risk of recurrence and progression to MIBC. Intravesical immunotherapy with BCG and chemotherapy are both considered adjuvant treatment options. However, it is challenging to define the optimum adjuvant therapy, particularly in intermediate-risk NMIBC cases. Considering the current BCG shortage, the risk-stratification tool for intermediate-risk patients is essential.
|
|
|
|
|
|
| Risk Stratification for Adjuvant Therapy with High Risk RCC
|
| Tian Zhang, MD
|
| Tian Zhang presents on the topic of risk stratification for adjuvant therapy in high-risk renal cell carcinoma (RCC). The presentation highlights the evolution of prognostic indicators and nomograms for RCC, which have significantly advanced since 2003, improving the selection process for adjuvant therapies and several key prognostic tools, including the UCLA integrated staging score, the Mayo Clinic/Leibovich score, and the ASSSURE nomogram, all of which help stratify patients based on risk and predict outcomes such as disease-free survival and overall survival.
|
|
|
|
|
|
|
|
|
|
|
| Artificial Intelligence and Prostate Cancer: Risk Stratification After Primary Therapy, ADT Treatment Intensification, and Evaluation of Metastatic Disease
|
| Zachary Klaassen, MD MSc, & Rashid K. Sayyid, MD MSc
|
| Artificial intelligence continues to transform the field of medicine, including the management of prostate cancer. In this Center of Excellence article, we discuss the contemporary literature evaluating artificial intelligence for risk stratification after primary therapy, ADT treatment intensification, and evaluation of metastatic disease.
|
|
|
|
|
|
| Development of a Novel Risk Stratification for Prostate Cancer Patients Candidate to Radical Prostatectomy Staged with Preoperative PSMA-PET: The Key Role of Molecular Imaging
|
| Francesco Barletta, MD
|
| Francesco Barletta discusses a novel risk stratification model for prostate cancer patients undergoing radical prostatectomy, incorporating preoperative PSMA-PET data to better predict biochemical failure (BCF). This new model demonstrated superior predictive accuracy and clinical net benefit compared to existing risk classifications, making it a valuable tool for improved patient management.
|
|
|
|
|
|
| Post-Prostatectomy Risk Stratification of Biochemical Recurrence Using Transfer Learning-Based Multi-Modal Artificial Intelligence
|
| Atallah Baydoun, MD, PhD
|
| Atallah Baydoun presented the results of an analysis evaluating post-prostatectomy risk stratification in the biochemical recurrence setting using transfer learning-based multi-modal artificial intelligence. For patients undergoing radical prostatectomy for prostate cancer, accurate risk stratification is essential to guide post-prostatectomy therapeutic decision making.
|
|
|
|
|
|
|
|
|
|
|
